Genstar-backed Signant Health Acquires Ametris: Implications for eCOA and Digital Outcome Measures
Decision brief
Answer first · skim in under a minute
Signant Health, backed by Genstar Capital, has acquired Ametris (formerly ActiGraph) from Archimed, creating an integrated platform for electronic clinical outcome assessments (eCOA) and wearable-derived digital measures. The deal consolidates two key clinical trial technology providers, with implications for study design, data quality, and vendor consolidation.
Signant Health acquired Ametris (formerly ActiGraph) on May 14, 2026, pairing electronic clinical outcome assessments with wearable-derived digital measures—an integration play aimed at sponsors tired of reconciling patient-reported and sensor data across multiple vendors.
Contents10 sections
Key Takeaways
- PR Newswire dated May 14, 2026 confirms Signant's acquisition of Ametris; terms were not disclosed.
- Ametris was formerly known as ActiGraph and focuses on wearable-derived digital health evidence.
- Signant positions the combined platform for traditional, virtual, and hybrid trials across eCOA and sensor analytics.
- Vendor consolidation may cut integration cost, but unified analytics roadmaps remain execution risk.
What did Signant announce?
Signant Health said it acquired Ametris, a global digital health solutions provider specializing in wearable-derived outcome measures.
The May 14, 2026 PR Newswire release frames the deal as uniting industry eCOA solutions with validated wearable digital outcome measures.
Jeremy Wyatt, identified as Ametris CEO in the release, emphasized regulatory-aligned wearable measures of physical activity and function joining Signant's COA franchise.
Why does eCOA-plus-wearables matter for sponsors?
Sponsors increasingly need both subjective patient reports and continuous objective activity or function data in the same evidence package.
Fragmented vendors create mapping errors when diaries, clinician assessments, and accelerometry live in separate systems.
A single contracting entity can simplify vendor management even before full technical convergence ships.
How should teams read FDA and EMA expectations?
Digital measures still require fit-for-purpose justification. FDA materials on clinical outcome assessment and related guidance, including documents hosted on fda.gov such as FDA COA-related guidance PDFs, remain the reference for US programs.
In Europe, sponsors must also respect the clinical trial regulatory framework summarized by EMA under the Clinical Trials Regulation pages when deploying combined eCOA/sensor workflows.
Neither agency treats a press-release platform claim as validated for labeling without study-specific endpoint negotiation.
What competitive dynamics change after the deal?
Bundled eCOA and wearables pressure multi-vendor stacks from large clinical-tech incumbents and niche sensor specialists.
Pricing opacity rises if Signant packages sensors with licenses; procurement teams should demand unbundled quotes during diligence.
Integration roadmaps matter more than Day-1 branding—ask for timelines on shared data models and audit trails.
What remains unproven?
Financial terms, Archimed exit details, and Genstar ownership narratives are not quantified in the PR Newswire primary and should not be invented.
An announced acquisition does not prove that unified analytics already exist in production for every therapeutic area.
Wearable endpoints still need disease-specific validation before they replace established primary outcomes.
What diligence questions should sponsors ask Signant after closing?
Request a written data-model map showing how eCOA instrument scores and wearable-derived features join in the same subject-visit key. Without that map, "end-to-end" remains marketing language.
Ask which therapeutic areas already have production integrations versus roadmap items. Neurology and rare-disease mobility studies may be farther along than oncology PRO packages.
Clarify audit-trail ownership for Part 11 / Annex 11 expectations when sensor firmware updates change derived endpoints mid-study.
Obtain reference sponsors willing to discuss reconciliation error rates before versus after dual-vendor setups. Anecdotes that only cite contracting simplicity are insufficient.
Pressure-test pricing: insist on unbundled eCOA licenses, device kits, analytics, and scientific consulting so procurement can compare against Medidata, Clario, and specialist wearables vendors on equal footing.
Confirm geographic device logistics and replacement SLAs for decentralized trials, because wearable failure rates can erase diary compliance gains if resupply is slow.
Sponsors should also inventory ongoing studies that already use ActiGraph- or Ametris-branded devices so change-control notices can be issued without protocol amendments that reopen ethics reviews. Where amendments are unavoidable, align them with upcoming monitoring visits rather than freezing enrollment. Keep a parallel exit option with a second sensor vendor until the integrated Signant analytics stack demonstrates at least one completed database lock under the combined quality system.
Document service-level credits for device failure and data gaps in the master services agreement before first patient in, so commercial leverage exists if wearable uptime falls short of protocol assumptions during pivotal collection windows.
Related NovaPharma coverage
Frequently Asked Questions
When did Signant Health acquire Ametris?
Signant Health announced the acquisition of Ametris (formerly ActiGraph) on May 14, 2026, according to its PR Newswire release. Financial terms were not disclosed.
What capabilities does the deal combine?
The companies say the deal unites Signant's electronic clinical outcome assessment (eCOA) tools with Ametris wearable-derived digital outcome measures to integrate patient-reported and sensor data.
Why do regulators care about digital outcome measures?
FDA and EMA guidance frameworks for clinical outcome assessments and trial conduct emphasize fit-for-purpose evidence. Sponsors still must justify how wearable endpoints support labeling claims.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
